| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) announced today new capability in advancing RNA biomarker analysis for gene and cell-based therapies.
RNAscope® in situ hybridization (ISH) is a new Interpace offering that can visualize, localize, and quantify gene expression within a single assay.
RNAscope® ISH utilizes unique "double Z" probes which can simultaneously provide signal amplification and background noise control, resulting in high sensitivity and specificity. Additionally, single-molecule visualization of the assay yields quantitative RNA expression and cell-specific expression within intact tissue architecture.
Application of RNAscope® ISH can streamline immune checkpoint target identification; visualize in vivo delivery of CAR-T therapeutic products; and differentiate therapeutic gene sequence from endogenous transcripts selection, even when there is no known or validated antibody.
According to Thomas Burnell, President and CEO of Interpace Biosciences, "RNAscope® truly unlocks the full potential of RNA biomarkers and is an excellent addition to our extensive immuno-oncology assay portfolio. This technology can predict target organ toxicity in preclinical models, confirm correct target site and on-target activity, and allow the ability to rapidly screen target nominees—across virtually any gene, species, tissue, and laboratory workflow." He continued, "We are proud to be one of a few select providers of this technology."
Posted In: IDXG
